Tag: HIV

Clinical Trials Healthcare & Pharmaceuticals News

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

Gilead

Gilead has announced positive Phase 3 results for its investigational single-tablet regimen (STR) of bictegravir and lenacapavir (BIC/LEN) in the ARTISTRY-2 trial. The new combination met its primary endpoint, demonstrating non-inferiority to BIKTARVY in maintaining viral suppression in adults with HIV-1. This novel two-drug regimen combines the potent integrase inhibitor bictegravir with the first-in-class capsid inhibitor lenacapavir, representing a potential new, simplified treatment option for long-term HIV management.

Clinical Trials Healthcare & Pharmaceuticals News

Gilead Unveils Promising New Data on Twice-Yearly HIV Prevention Drug Lenacapavir

Gilead

A key takeaway from the presentation is the strong preference for the twice-yearly injection over daily oral medication among trial participants. Over 75% of those surveyed expressed a preference for the injectable option, citing increased confidence in their protection against HIV and a lower risk of missing a dose.

Disease Biology Diseases

HIV – Human Immunodeficiency Virus | Details

HIV – Human Immunodeficiency Virus | Details and Diagnosis

HIV (human immunodeficiency virus) is a virus that attacks the human immune system, grouped under the genus Lentivirus and family retroviridae. Studies say that HIV infection in humans originated from a chimpanzee in Central Africa and the virus that affects chimpanzees is called as Simian immunodeficiency virus (SIV).